Kim Linton

Search results

• UK lead investigator NX-5948-301protocol

  Kim Linton (Other)

  Jul 2021 → …

  Activity: Other

• External peer review NIHR CARP application

  Kim Linton (Reviewer)

  2021

  Activity: Other

• PhD thesis: Non-codingRNAsinCancer

  Kim Linton (Examiner)

  25 Aug 2020

  Activity: Other

• UK lead investigator for Gen3013-02 trial

  Kim Linton (Other)

  2 Jul 2020 → …

  Activity: Other

• PhD thesis: Improving outcomes in patients with a diagnosis of pancreatic cancer

  Kim Linton (Other)

  18 Nov 2019

  Activity: Other

• External examiner PhD thesis

  Kim Linton (Examiner)

  4 Oct 2018

  Activity: Other

• UK lead investigator for MAGNOLIA clinical trial

  Kim Linton (Other)

  20 Feb 2018 → …

  Activity: Other

• Co-investigator NCRN investigator led clinical trial: A phase IIa study of RItuximab and VArlilumab in relapsed or refractory B-cell malignancies (RIVA trial)

  Kim Linton (Contributor)

  Jan 2017 → …

  Activity: Other

• Lecturer MSc Genomics Course

  Kim Linton (Lecturer)

  2017 → …

  Activity: Other

• Uk lead investigator for PCYC1143 clinical trial

  Kim Linton (Other)

  2017 → …

  Activity: Other

• Co-supervisor PhD project: Development of a novel software platform for automated prognostic pattern recognition in cancer using multiple biomarkers and multispectral microscopy (student Anna Maria Tsakiroglou)

  Kim Linton (Supervisor)

  Sept 2016 → …

  Activity: Other

• Systematic review on the Cost/Benefit of oncological Biosimilars upon their introduction in Europe and the USA

  Kim Linton (Advisor)

  20 Jul 2016

  Activity: Other

• Peer review MRC project grant application

  Kim Linton (Reviewer)

  15 Mar 2016

  Activity: Other

• Co-supervisor Intercalating BSc pathology project (student Syed Islam)

  Kim Linton (Supervisor)

  2016

  Activity: Other

• Lecturer Oxford Lymphoma Management Course

  Kim Linton (Other)

  2016 → …

  Activity: Other

• Co-supervisor Intercalating BSc pathology project (student Sophie Fitzpatrick)

  Kim Linton (Supervisor)

  2016

  Activity: Other

• Supervisor University of Salford MSc Advanced Practice (Health and Social Care) (student Jane Gibson)

  Kim Linton (Supervisor)

  2016 → …

  Activity: Other

• Co-investigator NCRN investigator led clinical trial: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma (PETReA)

  Kim Linton (Other)

  Dec 2015 → …

  Activity: Other

• Co-investigator NCRN clinical trial: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL) EudraCT number:2014-003588-39

  Kim Linton (Other)

  Aug 2015 → …

  Activity: Other

• UK co-ordinating investigator international clinical trial: Idelalisib Combination Study GS-US-401-1757: A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination with other Targeted Anti-cancer Therapies in Subjects with B-cell Malignancies

  Kim Linton (Other)

  Jul 2015 → Oct 2016

  Activity: Other

• UK co-ordinating investigator international clinical trial: ReBeL study - a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma. A HOVON/GLSG/NCRI study.

  Kim Linton (Other)

  Jun 2015 → …

  Activity: Other

• Co-investigator NCRN investigator led clinical trial: RomiCar - Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma

  Kim Linton (Other)

  Feb 2015 → …

  Activity: Other

• Peer Review PanMan Project Grant Application

  Kim Linton (Reviewer)

  18 Dec 2014

  Activity: Other

• Peer Review MCRC PhD Research Degree Proposal

  Kim Linton (Reviewer)

  25 Nov 2014

  Activity: Other

• Chief investigator on investigator-led clinical trial: randomised investigation of a diary for Patient Recorded Outcome Measures (PROMs)

  Kim Linton (Other)

  Nov 2014 → …

  Activity: Other

• Co-investigator NCRN investigator led clinical trial: BREVITY - A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity

  Kim Linton (Other)

  May 2014 → …

  Activity: Other

• Peer review MRC confidence in concept project grant applications

  Kim Linton (Reviewer)

  20 Mar 2014

  Activity: Other

• Lecturer MRes Oncology Chemotherapy Masterclass

  Kim Linton (Lecturer)

  2014 → …

  Activity: Other

• Peer Review Yorkshire Cancer Research project grant application

  Kim Linton (Reviewer)

  18 Sept 2013

  Activity: Other

• THE ARROVEN STUDY (MA25101): POST-AUTHORISATION OBSERVATIONAL SAFETY STUDY OF BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA

  Kim Linton (Other)

  Mar 2013 → Dec 2018

  Activity: Other

• Supervisor MRes Oncology Project: Immunohistochemical Sub-Classification of Diffuse Large B Cell Lymphoma: A Comparison of Standard and Automated Scoring Methods (student Samuel Reade)

  Kim Linton (Supervisor)

  2013 → 2014

  Activity: Other

• Peer review MCRC project grant application

  Kim Linton (Reviewer)

  7 Mar 2012

  Activity: Other

• Co-supervisor PhD project: Cardiotoxicity from cancer treatment: a Translational Approach to Biomarker Development (student Laura Cove-Smith)

  Kim Linton (Supervisor)

  2012 → 2015

  Activity: Other

• UK co-ordinating investigator international clinical trial: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

  Kim Linton (Other)

  2012 → 2016

  Activity: Other

• Co-investigator NCRN clinical trial: INCA trial - A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IO-R-CVP) versus Gemcitabine plus Rituximab and CVP (Gem-R-CVP) for the first line treatment of patients with diffuse large B cell lymphoma who are not suitable for anthracycline containing chemotherapy.

  Kim Linton (Other)

  Oct 2011

  Activity: Other

• Supervisor MRes Oncology project: Investigation into gene expression profiling of post-transplant lymphoproliferative disorder using archival formalin-fixed paraffin embedded tissue

  Kim Linton (Supervisor)

  2011 → 2012

  Activity: Other

• UK co-ordinating investigator international clinical trial: A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents

  Kim Linton (Other)

  Sept 2010 → Oct 2013

  Activity: Other

• Lecturer BSc Pathology Course - Cancer chemotherapy

  Kim Linton (Lecturer)

  2010 → 2020

  Activity: Other

• Supervisor MRes Oncology project: A Comparison between Fixed (FFPE) and Unfixed Lymphoma Samples by Affymetrix™ Gene Expression Microarrays (student Chris Howarth)

  Kim Linton (Supervisor)

  2010 → 2011

  Activity: Other